3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 1/2
2
Phase 1
2
Phase 3
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Dermatologic
2
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
61
Neoplasms
35
Colorectal Neoplasms
32
Neoplasm Metastasis
31
Breast Neoplasms
30
Prostatic Neoplasms
26
Pancreatic Neoplasms
26
Ovarian Neoplasms
26
Recurrence
25
Multiple Myeloma
25
Melanoma
23
Squamous Cell Carcinoma of Head and Neck
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Triple Negative Breast Neoplasms
17
Endometrial Neoplasms
17
Lymphoma, Large B-Cell, Diffuse
16
Lung Neoplasms
16
Glioblastoma
16
Lymphoma, Non-Hodgkin
15
Leukemia, Myeloid, Acute
14
Burkitt Lymphoma
14
Stomach Neoplasms
13
Small Cell Lung Carcinoma
12
Colonic Neoplasms
12
Carcinoma, Renal Cell
12
Uterine Cervical Neoplasms
11
Lymphoma
11
Glioma
11
Gastrointestinal Neoplasms
11
Lymphoma, Follicular
10
Interventions
fludarabine phosphate
1
fludarabine
1
Nivolumab
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 1/2
×
Uveal Melanoma
×
30 days
×
Clear all
NCT07627698
2026-06-04
DUET-MEL
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled
NCT03686124
2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2
Recruiting
375 enrolled